Cancer and pregnancy: Parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents

Mayo Clinic Proceedings

Volumn 84, Issue 11, 2009, Pages 985-1000

  Holtan, Shernan G ^a   Creedon, Douglas J ^a   Haluska, Paul ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; A 8301; AEG 35156; AEW 541; AFLIBERCEPT; ALXN 6000; AMG 102; ANTINEOPLASTIC AGENT; AP 12009; APO 010; AT 519; AXITINIB; BEVACIZUMAB; BEZ 235; BMS 690514; CEDIRANIB; CELECOXIB; CETUXIMAB; CHIR 265; CILENGITIDE; CNTO 95; CTCE 9908; CYC 10268; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; E 7080; E 7820; ERLOTINIB; EVEROLIMUS; GCS 100; GDC 0941; GRN 163L; GW 2580; IMC 1121B; LEXATUMUMAB; LY 2157299; MB 55; MG 59; MONOCLONAL ANTIBODY LM 609; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OA 5D5; OBLIMERSEN; PANITUMUMAB; PAZOPANIB; PF 0234106; PI 88; PLX 4032; PX 866; QUERCETIN; RAPAMYCIN; RHPS 4; SGX 523; SORAFENIB; SUNITINIB; TAE 226; TB 403; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; XL 147; XL 281; XL 647; XL 765; XL 880;

ADVANCED CANCER; ANGIOGENESIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CELL POLARITY; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MICROENVIRONMENT; MOTHER FETUS RELATIONSHIP; NATURAL KILLER CELL; NONHUMAN; NUTRIENT SUPPLY; PREGNANCY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SECOND TRIMESTER PREGNANCY; T LYMPHOCYTE; TROPHOBLAST; TUMOR CELL;

ACADEMIC MEDICAL CENTERS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNE SYSTEM PROCESSES; IMMUNOLOGIC FACTORS; MINNESOTA; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY; PREGNANCY TRIMESTER, THIRD;

EID: 71249138054     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.11.985     Document Type: Article

References (263)

1. Medawar PB. Some immunological and endocrinological problems raised by the evolution of viviparty in vertebrates. Symp Soc Exp Biol. 1953;7:320-338.
2. Clarke CA. Immunology of pregnancy: significance of blood group incompatibility between mother and foetus. Proc R Soc Med. 1968;61(11, pt 2):1213-1216.
3. Staun-Ram E, Shalev E. Human trophoblast function during the implantation process. Reprod Biol Endocrinol. 2005 Oct;3:56. (Pubitemid 41631195)
4. Lunghi L, Ferretti ME, Medici S, Biondi C, Vesce F. Control of human trophoblast function. Reprod Biol Endocrinol. 2007 Feb 8;5:6.
5. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol. 2008;20(2):183-189.
6. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther. 2009;8(1):1-9.
7. Liu TJ, LaFortune T, Honda T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007;6(4):1357-1367. (Pubitemid 46711999)
8. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12(20, pt 1):6144-6152. (Pubitemid 44703780)
9. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 2007;13(22, pt 1):6735-6742. (Pubitemid 350206811)
10. García-Echeverría C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5(3):231-239. (Pubitemid 38402115)
11. Conway JG, McDonald B, Parham J, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078- 16083. Epub 2005 Oct 25. (Pubitemid 41552870)
12. Irvine KM, Burns CJ, Wilks AF, Su S, Hume DA, Sweet MJ. A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations. FASEB J. 2006 Sep;20(11):1921-1923. Epub 2006 Jul 28.
13. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res. 2008;177:137-150.
14. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004;3(12):1011-1022. (Pubitemid 39642364)
15. Chen R, Wierda WG, Chubb S, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-4645. Epub 2009 Feb 20.
16. Squires MS, Feltell RE, Wallis NG, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009 Feb;8(2):324-332. Epub 2009 Jan 27.
17. Tojo M, Hamashima Y, Hanyu A, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-β. Cancer Sci. 2005;96(11):791-800. (Pubitemid 43019830)
18. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials - early lessons. J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):471-483. Epub 2008 Nov 21.
19. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007;13(19):5834-5840. (Pubitemid 47583908)
20. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 2008 Jul;26(19):3196-3203. Epub 2008 May 12.
21. Shen H, Moran DM, Maki CG. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008;68(20):8260-8268.
22. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis pref erentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 2006;66(15):7668-7677. (Pubitemid 44289225)
23. Prasad S, Kaur J, Roy P, Kalra N, Shukla Y. Theaflavins induce G2/M arrest by modulating expression of p21waf1/cip1, cdc25C and cyclin B in human prostate carcinoma PC-3 cells. Life Sci. 2007 Oct 13;81(17-18):1323-1331. Epub 2007 Sep 15. (Pubitemid 47599530)
24. Phase I study on monoclonal antibody TB-403 directed against PlGF in patients with solid tumours. ClinicalTrials.gov Web site. http://clinicaltrials. gov/ct2/show/NCT00702494. First received June 19, 2008. Last updated September 5, 2008. Accessed June 17, 2009.
25. Yodkeeree S, Chaiwangyen W, Garbisa S, Limtrakul P. Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. J Nutr Biochem. 2009 Feb;20(2):87-95. Epub 2008 May 20.
26. Lee KJ, Hwang SJ, Choi JH, Jeong HG. Saponins derived from the roots of Platycodon grandiflorum inhibit HT-1080 cell invasion and MMPs activities: regulation of NF-κB activation via ROS signal pathway. Cancer Lett. 2008 Sep;268(2):233-243. Epub May 21.
27. Tuynman JB, Vermeulen L, Boon EM, et al. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008;68(4):1213-1220. (Pubitemid 351272241)
28. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med. 2008;121(4):302-309.
29. Chiriva-Internati M, Grizzi F, Pinkston J, et al. Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim. 2006;42(3-4):89-95. (Pubitemid 44264512)
30. Chakraborty M, Wansley EK, Carrasquillo JA, et al. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res. 2008;14(13):4241-4249.
31. Adair SJ, Hogan KT. Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother. 2009 Apr;58(4):589-601. Epub 2008 Sep 13.
32. Poláková K, Bandzuchová E, Kuba D, Russ G. Demethylating agent 5-aza-2′-deoxycytidine activates HLA-G expression in human leukemia cell lines. Leuk Res. 2009 Apr;33(4):518-524. Epub 2008 Sep 26.
33. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 2002;62(22):6706-6711.
34. Macor P, Tripodo C, Zorzet S, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 2007;67(21):10556-10563. (Pubitemid 350070832)
35. Basu GD, Tinder TL, Bradley JM, et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol. 2006;177(4):2391-2402.
36. Jia L, Schweikart K, Tomaszewski J, et al. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol. 2008 Jan;46(1):203-211. Epub 2007 Aug 10. (Pubitemid 350235766)
37. Charrad RS, Li Y, Delpech B, et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med. 1999;5(6):669-676. (Pubitemid 29289431)
38. Song EY, Qu CF, Rizvi SM, et al. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther. 2008 Jan;7(1):76-80. Epub 2007 Oct 8.
39. Richman CM, Denardo SJ, O'Donnell RT, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005;11(16):5920-5927.
40. Mac Gabhann F, Popel AS. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: comparison of therapeutic approaches. PLOS Comput Biol. 2006 Dec 29;2(12):e180. Epub 2006 Nov 16.
41. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007 Jan;13(2, pt 2):709s-715s.
42. Verbrugge I, Wissink EH, Rooswinkel RW, et al. Combining radiotherapy with APO010 in cancer treatment. Clin Cancer Res. 2009 Mar 15;15(6):2031-2038. Epub 2009 Mar 10.
43. Dorgham K, Abadie V, Iga M, Hartley O, Gorochov G, Combadière B. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. Vaccine. 2008 Jun 19;26(26):3252-3260. Epub 2008 Apr 24.
44. Anderson DE. TIM-3 as a therapeutic target in human inflammatory diseases. Expert Opin Ther Targets. 2007;11(8):1005-1009. (Pubitemid 47232618)
45. Navabi H, Jasani B, Reece A, et al. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine. 2009 Jan 1;27(1):107-115. Epub 2008 Oct 31.
46. Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176(1):157-164. (Pubitemid 43023259)
47. Chauhan D, Li G, Podar K, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005;65(18):8350-8358. (Pubitemid 41330600)
48. Delaine T, Cumpstey I, Ingrassia L, et al. Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells. J Med Chem. 2008;51(24):8109-8114.
49. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol. 2008;180(92):699-705.
50. De Clercq E. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem. 2005;5(9):805-824. (Pubitemid 41167497)
51. Richert MM, Vaidya KS, Mills CN, et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep. 2009;21(3):761-767.
52. Gong M, Lu Z, Fang G, Bi J, Xue X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett. 2008 Dec 8;272(1):148-159. Epub 2008 Aug 9.
53. Sekulic A, Haluska P Jr, Miller AJ, et al; Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008;83(7):825-846.
54. Bulmer JN, Morrison L, Johnson PM. Expression of the proliferation markers Ki67 and transferrin receptor by human trophoblast populations. J Reprod Immunol. 1988;14(3):291-302. (Pubitemid 19018249)
55. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011-2015.
56. Blagoev KB. Cell proliferation in the presence of telomerase. PLoS One. 2009;4(2):e4622. Epub 2009 Feb 27.
57. Kyo S, Takakura M, Tanaka M, et al. Expression of telomerase activity in human chorion. Biochem Biophys Res Commun. 1997;241(2):498-503. (Pubitemid 28020129)
58. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580-584. (Pubitemid 28563719)
59. Lehner R, Bobak J, Kim NW, Shroyer AL, Shroyer KR. Localization of telomerase hTERT protein and survivin in placenta: relation to placental development and hydatidiform mole. Obstet Gynecol. 2001;97(6):965-970. (Pubitemid 32536697)
60. Fest S, Brachwitz N, Schumacher A, et al. Supporting the hypothesis of pregnancy as a tumor: survivin is upregulated in normal pregnant mice and participates in human trophoblast proliferation. Am J Reprod Immunol. 2008;59(1):75-83. (Pubitemid 350285585)
61. Shen J, Liu J, Long Y, et al. Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim Biophys Sin (Shanghai). 2009;41(3):223-230.
62. Zhen HN, Li LW, Zhang W, et al. Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol. 2007;31(5):1111-1117.
63. Congmin G, Mu Z, Yihui M, Hanliang L. Survivin - an attractive target for RNAi in non-Hodgkin's lymphoma, Daudi cell line as a model. Leuk Lymphoma. 2006;47(9):1941-1948. (Pubitemid 44649781)
64. Li QX, Zhao J, Liu JY, et al. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther. 2006 Jul;5(7):860-866. Epub 2006 Jul 9. (Pubitemid 44775148)
65. Forbes K, Westwood M, Baker PN, Aplin JD. Insulin-like growth factor I and II regulate the life cycle of trophoblast in the developing human placenta. Am J Physiol Cell Physiol. 2008 Jun;294(6):C1313-C1322. Epub 2008 Apr 9.
66. Boldt HB, Conover CA. Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res. 2007 Feb;17(1):10-18. Epub 2007 Jan 10.
67. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia [published correction appears in Nat Rev Cancer. 2009;9(3):224]. Nat Rev Cancer. 2008;8(12):915-928.
68. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Nat Clin Pract Oncol. 2007;4(10):591-602. (Pubitemid 47534758)
69. Hill DJ, Petrik J, Arany E. Growth factors and the regulation of fetal growth. Diabetes Care. 1998;21(suppl 2):B60-B69.
70. Papa V, Pezzino V, Costantino A, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1990;86(5):1503-1510. (Pubitemid 20372597)
71. Kalli KR, Conover CA. The insulin-like growth factor/insulin system in epithelial ovarian cancer. Front Biosci. 2003 May 1;8:d714-d722.
72. Marco DE, Cannas SA, Montemurro MA, Hu B, Cheng SY. Comparable ecological dynamics underlie early cancer invasion and species dispersal, involving self-organizing processes. J Theor Biol. 2009 Jan 7;256(1):65-75. Epub 2008 Oct 1.
73. Pollheimer J, Knöfler M. Signalling pathways regulating the invasive differentiation of human trophoblasts: a review. Placenta. 2005;26(suppl A):S21-S30. (Pubitemid 40500761)
74. Soundararajan R, Rao AJ. Trophoblast 'pseudo-tumorigenesis': significance and contributory factors. Reprod Biol Endocrinol. 2004 Mar 25;2:15. doi: 10.1186/1477-7827-2-15.
75. Ferretti C, Bruni L, Dangles-Marie V, Pecking AP, Bellet D. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. 2007 Mar-Apr;13(2):121-141. Epub 2006 Oct 26. (Pubitemid 46323191)
76. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818-829. (Pubitemid 351757205)
77. Vicovac L, Aplin JD. Epithelial-mesenchymal transition during trophoblast differentiation. Acta Anat (Basel). 1996;156(3):202-216.
78. Floridon C, Nielsen O, Holund B, et al. Localization of E-cadherin in villous, extravillous and vascular trophoblasts during intrauterine, ectopic and molar pregnancy. Mol Hum Reprod. 2000;6(10):943-950. (Pubitemid 30744830)
79. Blechschmidt K, Mylonas I, Mayr D, et al. Expression of E-cadherin and its repressor snail in placental tissue of normal, preeclamptic and HELLP pregnancies. Virchows Arch. 2007;450(2):195-202. (Pubitemid 46295231)
80. Matalon ST, Drucker L, Fishman A, Ornoy A, Lishner M. The role of heat shock protein 27 in extravillous trophoblast differentiation. J Cell Biochem. 2008;103(3):719-729. (Pubitemid 351240609)
81. Jäättelä M. Escaping cell death: survival proteins in cancer. Exp Cell Res. 1999;248(1):30-43. (Pubitemid 29393927)
82. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(2):86-103.
83. LaMarca HL, Dash PR, Vishnuthevan K, et al. Epidermal growth factor-stimulated extravillous cytotrophoblast motility is mediated by the activation of PI3-K, Akt and both p38 and p42/44 mitogen-activated protein kinases. Hum Reprod. 2008 Aug;23(8):1733-1741. Epub 2008 May 16. (Pubitemid 352020009)
84. Binker MG, Binker-Cosen AA, Richards D, Oliver B, Cosen-Binker LI. EGF promotes invasion by PANC-1 cells through Rac1/ROS-dependent secretion and activation of MMP-2. Biochem Biophys Res Commun. 2009 Feb 6;379(2):445-450. Epub 2008 Dec 29.
85. Pollheimer J, Loregger T, Sonderegger S, et al. Activation of the canonical wingless/T-cell factor signaling pathway promotes invasive differentiation of human trophoblast. Am J Pathol. 2006;168(4):1134-1147.
86. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17(1):45-51.
87. Xie H, Tranguch S, Jia X, et al. Inactivation of nuclear Wnt-β-catenin signaling limits blastocyst competency for implantation. Development. 2008 Feb;135(4):717-727. Epub 2008 Jan 16.
88. Grisaru-Granovsky S, Maoz M, Barzilay O, Yin YJ, Prus D, Bar-Shavit R. Protease activated receptor-1, PAR1, promotes placenta trophoblast invasion and β-catenin stabilization. J Cell Physiol. 2008;218(3):512-521.
89. Even-Ram SC, Grisaru-Granovsky S, Pruss D, et al. The pattern of expression of protease-activated receptors (PARs) during early trophoblast development. J Pathol. 2003;200(1):47-52. (Pubitemid 36592635)
90. Salah Z, Haupt S, Maoz M, et al. p53 controls hPar1 function and expression. Oncogene. 2008 Nov;27(54):6866-6874. Epub 2008 Sep 29.
91. Goerge T, Barg A, Schnaeker EM, et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res. 2006;66(15):7766-7774. (Pubitemid 44289237)
92. Fitzgerald JS, Poehlmann TG, Schleussner E, Markert UR. Trophoblast invasion: the role of intracellular cytokine signalling via signal transducer and activator of transcription 3 (STAT3). Hum Reprod Update. 2008 Jul-Aug;14(4):335-344. Epub 2008 Apr 17. (Pubitemid 351858973)
93. Zybina TG, Frank HG, Biesterfeld S, Kaufmann P. Genome multiplication of extravillous trophoblast cells in human placenta in the course of differentiation and invasion into endometrium and myometrium: II, Mechanisms of polyploidization. Tsitologiia. 2004;46(7):640-648.
94. MacAuley A, Cross JC, Werb Z. Reprogramming the cell cycle for endoreduplication in rodent trophoblast cells. Mol Biol Cell. 1998;9(4):795-807. (Pubitemid 28173633)
95. Lanzi C, Cassinelli G, Cuccuru G, et al. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate. 2001;48(4):254-264. (Pubitemid 32816551)
96. Puig PE, Guilly MN, Bouchot A, et al. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int. 2008 Sep;32(9):1031-1043. Epub 2008 May 2.
97. Zhou Y, Fisher SJ, Janatpour M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate: a strategy for successful endovascular invasion? J Clin Invest. 1997;99(9):2139-2151. (Pubitemid 27203770)
98. Robertson GP. Mig-7 linked to vasculogenic mimicry. Am J Pathol. 2007;170(5):1454-1456.
99. Maquoi E, van den Brûle FA, Castronovo V, Foidart JM. Changes in the distribution pattern of galectin-1 and galectin-3 in human placenta correlates with the differentiation pathways of trophoblasts. Placenta. 1997;18(5-6):433-439. (Pubitemid 27326313)
100. Mourad-Zeidan AA, Melnikova VO, Wang H, Raz A, Bar-Eli M. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol. 2008 Dec;173(6):1839-1852. Epub 2008 Nov 6.
101. Iurisci I, Cumashi A, Sherman AA, et al; Consorzio Interuniversitario Nazionale Per la Bio-Oncologia (Cinbo), Italy. Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res. 2009;29(1):403-410.
102. Phillips TM, Lindsey JS. Carcinoma cell-specific Mig-7: a new potential marker for circulating and migrating cancer cells. Oncol Rep. 2005;13(1):37-44.
103. Petty AP, Garman KL, Winn VD, Spidel CM, Lindsey JS. Overexpression of carcinoma and embryonic cytotrophoblast cell-specific Mig-7 induces invasion and vessel-like structure formation. Am J Pathol. 2007;170(5):1763-1780.
104. van der Schaft DW, Seftor RE, Seftor EA, et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. 2004;96(19):1473-1477.
105. Condeelis J, Singer RH, Segall JE. The great escape: when cancer cells hijack the genes for chemotaxis and motility [published online ahead of print July 5, 2005]. Annu Rev Cell Dev Biol. 2005 Nov;21:695-718.
106. Schiessl B, Innes BA, Bulmer JN, et al. Localization of angiogenic growth factors and their receptors in the human placental bed throughout normal human pregnancy. Placenta. 2009 Jan;30(1):79-87. Epub 2008 Nov 17.
107. Cao Y, Liu Q. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res. 2007;97:203-224. (Pubitemid 46528989)
108. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3(1):24-40. (Pubitemid 43108832)
109. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat. 2008 Dec;11(6):219-230. Epub 2008 Oct 23.
110. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131(3):463-475. (Pubitemid 350007692)
111. Loges S, Roncal C, Carmeliet P. Development of targeted angiogenic medicine. J Thromb Haemost. 2009 Jan;7(1):21-33. Epub. 2008 Oct 25.
112. Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta. 1997;18(8):657-665. (Pubitemid 27448423)
113. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients [letter]. J Clin Oncol. 2005;23(31):8136-8139. (Pubitemid 46657433)
114. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22.
115. Wen HY, Abbasi S, Kellems RE, Xia Y. mTOR: a placental growth signaling sensor. Placenta. 2005;26(suppl A):S63-S69. (Pubitemid 40500768)
116. Roos S, Jansson N, Palmberg I, Säljö K, Powell TL, Jansson T. Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. J Physiol. 2007 Jul 1;582(pt 1):449-459. Epub 2007 Apr 26. (Pubitemid 46993587)
117. Abraham RT, Eng CH. Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets. 2008;12(2):209-222. (Pubitemid 351284963)
118. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15(5):1612-1622. Epub 2009 Feb 17.
119. Mor G. Pregnancy reconceived: what keeps a mother's immune system from treating her baby as foreign tissue? A new theory resolves the paradox. Natural History. May 1, 2007.
120. Moffett-King A. Natural killer cells and pregnancy [published correction appears in Nat Rev Immunol. 2002;2(12):975]. Nat Rev Immunol. 2002;2(9):656-663.
121. Chiou SH, Sheu BC, Chang WC, Huang SC, Hong-Nerng H. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol. 2005 Oct;67(1-2):35-50. Epub 2005 Aug 18. (Pubitemid 41415554)
122. Carlino C, Stabile H, Morrone S, et al. Recruitment of circulating NK cells through decidual tissues: a possible mechanism controlling NK cell accumulation in the uterus during early pregnancy. Blood. 2008 Mar 15;111(6):3108-3115. Epub 2008 Jan 10.
123. Verma S, Hiby SE, Loke YW, King A. Human decidual natural killer cells express the receptor for and respond to the cytokine interleukin 15. Biol Reprod. 2000;62(4):959-968. (Pubitemid 30173809)
124. Keskin DB, Allan DS, Rybalov B, et al. TGFβ promotes conversion of CD16+ peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells. Proc Natl Acad Sci U S A. 2007 Feb;104(9):3378-3383. Epub 2007 Feb 20. (Pubitemid 46364167)
125. Koopman LA, Kopcow HD, Rybalov B, et al. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med. 2003;198(8):1201-1212. (Pubitemid 37323385)
126. Hanna J, Goldman-Wohl D, Hamani Y, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006 Sep;12(9):1065-1074. Epub 2006 Aug 6. (Pubitemid 44353388)
127. Saito S, Nakashima A, Myojo-Higuma S, Shiozaki A. The balance between cytotoxic NK cells and regulatory NK cells in human pregnancy. J Reprod Immunol. 2008 Jan;77(1):14-22. Epub 2007 Jun 11.
128. Wald O, Weiss ID, Wald H, et al. IFN-γ acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol. 2006;176(8):4716-4729.
129. Wittnebel S, Da Rocha S, Giron-Michel J, et al. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res. 2007;67(12):5594-5599. (Pubitemid 46991962)
130. Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863-875. (Pubitemid 351240580)
131. Abumaree MH, Stone PR, Chamley LW. The effects of apoptotic, deported human placental trophoblast on macrophages: possible consequences for pregnancy. J Reprod Immunol. 2006;72(1-2):33-45. Epub 2006 Jul 14.
132. Gustafsson C, Mjösberg J, Matussek A, et al. Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. PLoS One. 2008;3(4):e2078. (Pubitemid 352025020)
133. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-κB. Blood. 2009 Apr 2;113(14):3139-3146. Epub 2009 Jan 26.
134. Hagemann T, Lawrence T, McNeish I, et al. "Re-educating" tumor-associated macrophages by targeting NF-κB. J Exp Med. 2008 Jun;205(6):1261-1268. Epub May 19. (Pubitemid 351831483)
135. Heikkinen J, Möttönen M, Alanen A, Lassila O. Phenotypic characterization of regulatory T cells in the human decidua. Clin Exp Immunol. 2004;136(2):373-378. (Pubitemid 38543459)
136. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology. 2004;112(1):38-43. (Pubitemid 38609820)
137. Zhao JX, Zeng YY, Liu Y. Fetal alloantigen is responsible for the expansion of the CD4(+)CD25(+) regulatory T cell pool during pregnancy. J Reprod Immunol. 2007 Oct;75(2):71-81. Epub 2007 Aug 7. (Pubitemid 47384866)
138. Schumacher A, Wafula PO, Bertoja AZ, et al. Mechanisms of action of regulatory T cells specific for paternal antigens during pregnancy. Obstet Gynecol. 2007;110(5):1137-1145. (Pubitemid 350059421)
139. Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod. 2004 May;10(5):347-353. Epub 2004 Mar 2. (Pubitemid 38714366)
140. Steinborn A, Haensch GM, Mahnke K, et al. Distinct subsets of regulatory T cells during pregnancy: is the imbalance of these subsets involved in the pathogenesis of preeclampsia? Clin Immunol. 2008 Dec;129(3):401-412. Epub 2008 Sep 21.
141. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108(3):804-811.
142. +CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol. 2009 Apr;131(1):109-118. Epub 2009 Jan 18.
143. + lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol. 2008 Aug;110(2):216-221. Epub 2008 Jun 3.
144. Piersma SJ, Welters MJ, van der Burg SH. Tumor-specific regulatory T cells in cancer patients. Hum Immunol. 2008 Apr-May;69(4-5):241-249. Epub 2008 Mar 28.
145. Beyer M, Schultze JL. Immunoregulatory T cells: role and potential as a target in malignancy. Curr Oncol Rep. 2008;10(2):130-136.
146. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7(11):880-887. (Pubitemid 350006256)
147. Zhang L, Dermawan KT, Jin ML, Xiong SD, Chu YW. Does chemotherapy augment
148. Miyazaki S, Tsuda H, Sakai M, et al. Predominance of Th2-promoting dendritic cells in early human pregnancy decidua. J Leukoc Biol. 2003 Oct;74(4):514-522. Epub 2003 Jul 15. (Pubitemid 38040378)
149. + dendritic cells. Am J Pathol. 2000;157(1):159-169.
150. Plaks V, Birnberg T, Berkutzki T, et al. Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest. 2008 Dec;118(12):3954-3965. Epub 2008 Nov 20.
151. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008 Aug;8(8):618-631. Epub 2008 Jul 17.
152. Hunt JS, Orr HT. HLA and maternal-fetal recognition. FASEB J. 1992;6(6):2344-2348.
153. Hunt JS, Andrews GK, Wood GW. Normal trophoblasts resist induction of class I HLA. J Immunol. 1987;138(8):2481-2487.
154. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27(45):5869-5885.
155. Marchal JA, Boulaiz H, Rodriguez-Serrano F, et al. 5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation. Med Chem. 2007;3(3):233-239. (Pubitemid 46794884)
156. Fonsatti E, Nicolay HJ, Sigalotti L, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′- deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res. 2007;13(11):3333-3338. (Pubitemid 46944920)
157. McMaster MT, Librach CL, Zhou Y, et al. Human placental HLAG expression is restricted to differentiated cytotrophoblasts. J Immunol. 1995;154(8):3771-3778.
158. Arnaiz-Villena A, Morales P, Gomez-Casado E, et al. Evolution of MHC-G in primates: a different kind of molecule for each group of species. J Reprod Immunol. 1999;43(2):111-125. (Pubitemid 29349676)
159. Hunt JS, Langat DK, McIntire RH, Morales PJ. The role of HLA-G in human pregnancy. Reprod Biol Endocrinol. 2006;4(suppl 1):S10.
160. Caumartin J, Favier B, Daouya M, et al. Trogocytosis-based generation of suppressive NK cells. EMBO J. 2007 Mar 7;26(5):1423-1433. Epub 2007 Feb 22.
161. Amiot L, Le Friec G, Sebti Y, et al. HLA-G and lymphoproliferative disorders. Semin Cancer Biol. 2003;13(5):379-385.
162. Bezuhly M, Howlett A, Colp P, et al. Quantitative HLA-G expression in metastasising and non-metastasising primary thin cutaneous melanomas [letter]. Dermatology. 2008;217(3):281-283. Epub 2008 Aug 7.
163. Kleinberg L, Flørenes VA, Skrede M, et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006 Jul;449(1):31-39. Epub 2006 Mar 16. (Pubitemid 43988363)
164. Davidson B, Elstrand MB, McMaster MT, et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol. 2005;96(1):42-47. (Pubitemid 39612415)
165. Seliger B, Schlaf G. Structure, expression and function of HLA-G in renal cell carcinoma. Semin Cancer Biol. 2007;17(6):444-450. Epub 2007 Jul 13. (Pubitemid 350052590)
166. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of HLAG is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 2007;128(6):1002-1009.
167. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol. 2007 Oct;14(10):2721-2729. Epub 2007 Jun 13. (Pubitemid 47460633)
168. Yoon BS, Kim YT, Kim JW, Kim SH, Kim JH, Kim SW. Expression of human leukocyte antigen-G and its correlation with interleukin-10 expression in cervical carcinoma. Int J Gynaecol Obstet. 2007Jul;98(1):48-53. Epub 2007 May 9.
169. Boucher LD, Yoneda K. The expression of trophoblastic cell markers by lung carcinomas. Hum Pathol. 1995;26(11):1201-1206.
170. El-Chennawi FA, Auf FA, El-Diasty AM, et al. Expression of HLA-G in cancer bladder. Egypt J Immunol. 2005;12(1):57-64.
171. Langat DK, Sue Platt J, Tawfik O, Fazleabas AT, Hunt JS. Differential expression of human leukocyte antigen-G (HLA-G) messenger RNAs and proteins in normal human prostate and prostatic adenocarcinoma. J Reprod Immunol. 2006 Aug;71(1):75-86. Epub 2006 Apr 17. (Pubitemid 43975139)
172. Barrier BF, Kendall BS, Sharpe-Timms KL, Kost ER. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol. 2006 Oct;103(1):25-30. Epub 2006 Mar 10.
173. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007 Mar;20(3):375-383. Epub 2007 Feb 2. (Pubitemid 46348337)
174. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003;13(5):371-377.
175. Yan WH, Lin A, Chen BG, et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med. 2008;12(3):889-898. (Pubitemid 351718068)
176. Veit TD, Chies JA. Tolerance versus immune response: MicroRNAs as important elements in the regulation of the HLA-G gene expression. Transpl Immunol. 2009 Mar;20(4):229-231. Epub 2008 Nov 25.
177. Onno M, Guillaudeux T, Amiot L, et al. The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. Hum Immunol. 1994;41(1):79-86. (Pubitemid 24319055)
178. Komohara Y, Harada M, Ishihara Y, et al. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep. 2007;18(6):1463-1468.
179. Clark DA, Keil A, Chen Z, Markert U, Manuel J, Gorczynski RM. Placental trophoblast from successful human pregnancies expresses the tolerance signaling molecule, CD200 (OX-2). Am J Reprod Immunol. 2003;50(3):187-195. (Pubitemid 37038157)
180. Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma [published correction appears in Blood. 2007;109(7):2717]. Blood. 2006 Dec 15;108(13):4194-4197. Epub 2006 Aug 31.
181. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia [letter]. Leukemia. 2007 Mar;21(3):566-568. Epub 2007 Jan 25. (Pubitemid 46306574)
182. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother. 2008;57(7):987-996.
183. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol. 2008 Oct;29(10):464-468. Epub 2008 Sep 3.
184. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol. 2006;6(6):433-446.
185. Briese J, Oberndörfer M, Pätschenik C, et al. Osteopontin is colocalized with the adhesion molecule CEACAM1 in the extravillous trophoblast of the human placenta and enhances invasion of CEACAM1-expressing placental cells. J Clin Endocrinol Metab. 2005 Sep;90(9):5407-5413. Epub 2005 Jun 14. (Pubitemid 41262309)
186. Dango S, Sienel W, Schreiber M, et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. Lung Cancer. 2008 Jun;60(3):426-433. Epub 2008 Jan 22.
187. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20:2530-2536. (Pubitemid 34525740)
188. Phillips TA, Ni J, Hunt JS. Death-inducing tumour necrosis factor (TNF) superfamily ligands and receptors are transcribed in human placentae, cytotrophoblasts, placental macrophages and placental cell lines. Placenta. 2001;22(8-9):663-672. (Pubitemid 32982702)
189. Phillips TA, Ni J, Pan G, et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J Immunol. 1999;162(10):6053-6059. (Pubitemid 29314964)
190. Petroff MG, Chen L, Phillips TA, Azzola D, Sedlmayr P, Hunt JS. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol Reprod. 2003;68(5):1496-1504. Epub 2002 Nov 27. (Pubitemid 36519751)
191. van Mourik MS, Macklon NS, Heijnen CJ. Embryonic implantation: cytokines, adhesion molecules, and immune cells in establishing an implantation environment. J Leukoc Biol. 2009 Jan;85:4-19. Epub 2008 Sep 17.
192. Kao LC, Tulac S, Lobo S, et al. Global gene profiling in human endometrium during the window of implantation. Endocrinology. 2002;143(6):2119-2138. (Pubitemid 34521559)
193. Franchi A, Zaret J, Zhang X, Bocca S, Oehninger S. Expression of immunomodulatory genes, their protein products and specific ligands/receptors during the window of implantation in the human endometrium. Mol Hum Reprod. 2008;14(7):413-421. (Pubitemid 351984802)
194. Spendlove I, Ramage JM, Bradley R, Harris C, Durrant LG. Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol Immunother. 2006;55(8):987-995. (Pubitemid 43673590)
195. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19(5-6):333-345.
196. Renkl AC, Wussler J, Ahrens T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood. 2005; 106(3):946-955. (Pubitemid 41076439)
197. Weber GF. Molecular mechanisms of metastasis. Cancer Lett. 2008;270(2):181-190.
198. Weber GF, Ashkar S, Cantor H. Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians. 1997;109(1):1-9. (Pubitemid 27161044)
199. Fraccaroli L, Alfieri J, Larocca L, et al. A potential tolerogenic immune mechanism in a trophoblast cell line through the activation of chemokine-induced T cell death and regulatory T cell modulation. Hum Reprod. 2009 Jan;24(1):166-175. Epub 2008 Sep 29.
200. Mellado M, de Ana AM, Moreno MC, Martínez C, Rodríguez- Frade JM. A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr Biol. 2001;11(9):691-696. (Pubitemid 32418165)
201. Fest S, Aldo PB, Abrahams VM, et al. Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol. 2007;57(1):55-66. (Pubitemid 44911607)
202. Ancrile BB, O'Hayer KM, Counter CM. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol Interv. 2008;8(1):22-27.
203. Stathopoulos GT, Psallidas I, Moustaki A, et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst. 2008 Oct 15;100(20):1464-1476. Epub 2008 Oct 7.
204. Koga M, Kai H, Egami K, et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun. 2008 Jan 11;365(2):279-284. Epub 2007 Nov 6. (Pubitemid 350137285)
205. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735-6741.
206. von Rango U, Krusche CA, Beier HM, Classen-Linke I. Indoleamine- dioxygenase is expressed in human decidua at the time maternal tolerance is established. J Reprod Immunol. 2007 Jun;74(1-2):34-45. Epub 2007 Feb 26. (Pubitemid 46679063)
207. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008 Apr;222:206-221.
208. Schröcksnadel H, Baier-Bitterlich G, Dapunt O, Wachter H, Fuchs D. Decreased plasma tryptophan in pregnancy. Obstet Gynecol. 1996;88(1):47-50.
209. López AS, Alegre E, LeMaoult J, Carosella E, González A. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol Immunol. 2006 Jul;43(14):2151-2160. Epub 2006 Feb 21. (Pubitemid 43831200)
210. von Bergwelt-Baildon MS, Popov A, Saric T, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 2006 Jul 1;108(1):228-237. Epub 2006 Mar 7. (Pubitemid 43990633)
211. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol. 2006 Apr;18(2):220-225. Epub 2006 Feb 7.
212. Sayama S, Yoshida R, Oku T, Imanishi J, Kishida T, Hayaishi O. Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc Natl Acad Sci U S A. 1981;78(12):7327-7330. (Pubitemid 12186133)
213. von Rango U. Fetal tolerance in human pregnancy - a crucial balance between acceptance and limitation of trophoblast invasion. Immunol Lett. 2008 Jan 15;115(1):21-32. Epub 2007 Nov 5. (Pubitemid 350298587)
214. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999;18(1):65-73. (Pubitemid 29411092)
215. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485-487. (Pubitemid 27343304)
216. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008 Nov;205(12):2763-2779. Epub 2008 Nov 10.
217. Taylor DD, Akyol S, Gercel-Taylor C. Pregnancy-associated exosomes and their modulation of T cell signaling. J Immunol. 2006;176(3):1534-1542. (Pubitemid 43134297)
218. Redman CW, Sargent IL. Microparticles and immunomodulation in pregnancy and pre-eclampsia. J Reprod Immunol. 2007 Dec;76(1-2):61-67. Epub 2007 May 4.
219. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569-579.
220. Amin C, Mackman N, Key NS. Microparticles and cancer. Pathophysiol Haemost Thromb. 2008;36(3-4):177-183. Epub 2009 Jan 27.
221. Riteau B, Faure F, Menier C, et al. Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol. 2003;64(11):1064-1072. (Pubitemid 37413716)
222. Alix-Panabières C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008;14(16):5013-5021.
223. Mueller UW, Hawes CS, Wright AE, et al. Isolation of fetal trophoblast cells from peripheral blood of pregnant women. Lancet. 1990;336(8709):197-200.
224. Evans PC, Lambert N, Maloney S, Furst DE, Moore JM, Nelson JL. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood. 1999;93(6):2033-2037. (Pubitemid 29128506)
225. Gilmore GL, Haq B, Shadduck RK, Jasthy SL, Lister J. Fetal-maternal microchimerism in normal parous females and parous female cancer patients. Exp Hematol. 2008 Sep;36(9):1073-1077.
226. Dubernard G, Oster M, Chareyre F, et al. Increased fetal cell microchimerism in high grade breast carcinomas occurring during pregnancy. Int J Cancer. 2009;124(5):1054-1059.
227. Nguyen Huu S, Oster M, Avril MF, et al. Fetal microchimeric cells participate in tumour angiogenesis in melanomas occurring during pregnancy. Am J Pathol. 2009 Feb;174(2):630-637. Epub 2009 Jan 15.
228. Hunt JS, Jadhav L, Chu W, Geraghty DE, Ober C. Soluble HLA-G circulates in maternal blood during pregnancy. Am J Obstet Gynecol. 2000;183(3):682-688.
229. van der Meer A, Lukassen HG, van Cranenbroek B, et al. Soluble HLAG promotes Th1-type cytokine production by cytokine-activated uterine and peripheral natural killer cells. Mol Hum Reprod. 2007 Feb;13(2):123-133. Epub 2006 Nov 22. (Pubitemid 46152599)
230. Contini P, Ghio M, Poggi A, et al. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol. 2003;33(1):125-134. (Pubitemid 36157650)
231. Puppo F, Contini P, Ghio M, Indiveri F. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction. Scientific World Journal. 2002 Feb;2:421-423.
232. Gros F, Sebti Y, de Guibert S, et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia. 2006;8(3):223-230. (Pubitemid 43671238)
233. Leleu X, Le Friec G, Facon T, et al; Intergroupe Francophone du Myélome. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2005;11(20):7297-7303.
234. Sebti Y, Le Friec G, Pangault C, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol. 2003;64(11):1093-1101. (Pubitemid 37413719)
235. Dunker K, Schlaf G, Bukur J, Altermann WW, Handke D, Seliger B. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens. 2008;72(2):137-148. (Pubitemid 352009822)
236. Urosevic M, Kurrer MO, Kamarashev J, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001;159(3):817-824. (Pubitemid 32847172)
237. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002;168(9):4772-4780. (Pubitemid 34441386)
238. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen - G serum level is elevated in melanoma patients and is further increased by interferon-α immunotherapy. Cancer. 2001;92(2):369-376. (Pubitemid 32664444)
239. Morandi F, Levreri I, Bocca P, et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007;67(13):6433-6441. (Pubitemid 47037528)
240. Dong M, Ding G, Zhou J, Wang H, Zhao Y, Huang H. The effect of trophoblasts on T lymphocytes: possible regulatory effector molecules - a proteomic analysis. Cell Physiol Biochem. 2008;21(5-6):463-472. Epub 2008 Apr 24. (Pubitemid 351620300)
241. Salahshor S, Goncalves J, Chetty R, Gallinger S, Woodgett JR. Differential gene expression profile reveals deregulation of pregnancy specific beta1 glycoprotein 9 early during colorectal carcinogenesis. BMC Cancer. 2005 Jun 27;5:66. (Pubitemid 41461065)
242. Fagnart OC, Cambiaso CL, Lejeune MD, Noel G, Maisin H, Masson PL. Prognostic value of concentration of pregnancy-specific β1-glycoprotein (SP1) in serum of patients with breast cancer. Int J Cancer. 1985;36(5):541-544.
243. Song M, Ramaswamy S, Ramachandran S, et al. Angiogenic role for glycodelin in tumorigenesis. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9265-9270. Epub 2001 Jul 17.
244. Kang SY, Watnick RS. Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF expression. APMIS. 2008;116(7-8):638-647.
245. Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med. 2007 Jan;85(1):15-22. Epub 2006 Nov 15. (Pubitemid 46020939)
246. Rendon BE, Willer SS, Zundel W, Mitchell RA. Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol. 2009 Jun;86(3):180-185. Epub 2009 Jan 7.
247. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5(1):29-41.
248. Rabinovich GA, Liu FT, Hirashima M, Anderson A. An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand J Immunol. 2007;66(2-3):143-158. (Pubitemid 47063211)
249. Kusanovic JP, Romero R, Hassan SS, et al. Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J Matern Fetal Neonatal Med. 2007;20(12):867-878. (Pubitemid 350207566)
250. Casasnovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007 May 1;25(13):1732-1740. Epub 2007 Mar 26. (Pubitemid 46797954)
251. Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martínez-Maza O. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol. 2006;27(4):187-194. Epub 2006 Apr 27. (Pubitemid 43752197)
252. high regulatory T cells in human pregnancy. J Reprod Immunol. 2005;65(2):111-120.
253. Rukavina D, Podack ER, Rubesa G, Spanjol-Pandelo S, Randic L. Down-regulated expression of perforin-positive/CD16+ cells in the peripheral blood lymphocytes in the first trimester of pregnancy and up-regulation at the end of pregnancy. Am J Reprod Immunol. 1997;38(3):189-196. (Pubitemid 27379530)
254. Barakonyi A, Miko E, Varga P, Szekeres-Bartho J. V-chain preference of gamma/delta T-cell receptors in peripheral blood during term labor. Am J Reprod Immunol. 2008;59(3):201-205. (Pubitemid 351250419)
255. Vassiliadis S, Ranella A, Papadimitriou L, Makrygiannakis A, Athanassakis I. Serum levels of pro- and anti-inflammatory cytokines in non-pregnant women, during pregnancy, labour and abortion. Mediators Inflamm. 1998;7(2):69-72. (Pubitemid 28238116)
256. Haddad R, Tromp G, Kuivaniemi H, et al. Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature. Am J Obstet Gynecol. 2006;195(2):394.e1-394.e24.
257. Bollopragada S, Youssef R, Jordan F, Greer I, Norman J, Nelson S. Term labor is associated with a core inflammatory response in human fetal membranes, myometrium, and cervix. Am J Obstet Gynecol. 2009;200(1):104. e1-104.e11.
258. Christiaens I, Zaragoza DB, Guilbert L, Robertson SA, Mitchell BF, Olson DM. Inflammatory processes in preterm and term parturition. J Reprod Immunol. 2008 Oct;79(1):50-57. Epub 2008 Jun 11.
259. Winn VD, Haimov-Kochman R, Paquet AC, et al. Gene expression profiling of the human maternal-fetal interface reveals dramatic changes between midgestation and term. Endocrinology. 2007 Mar;148(3):1059-1079. Epub 2006 Dec 14. (Pubitemid 46272792)
260. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN; Melanoma Study Group of the Mayo Clinic Cancer Center. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res. 2009 Mar 15;15(6):1931-1939. Epub 2009 Feb 24.
261. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther. 2005 Sep;4(9):1018-1029. Epub 2005 Sep 9. (Pubitemid 41598600)
262. Talantov D, Mazumder A, Yu JX, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005;11(20):7234-7242. (Pubitemid 41507680)
263. Mikheev AM, Nabekura T, Kaddoumi A, et al. Profiling gene expression in human placentae of different gestational ages: an OPRU Network and UW SCOR Study. Reprod Sci. 2008;15(9):866-877.